本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
「元宇宙」（Metaverse），成為2021年最轟動、吸引最多眼球的熱門話題，世界各大科技龍頭紛紛搶先進入了這一條元宇宙的賽道裡，不久前，首個元宇宙國際標準聯盟正式成立，這個名為「元宇宙標準論壇」（Metaverse Standards Forum）的組織則是由全球數十家科技行業巨頭組成，包括Meta、Microsoft 、微軟、Epic Games、Adobe、NVIDIA、高通、阿里巴巴、Sony、Unity 等共同組成，如上述可見，產業領域跨度很大。該組織成立的目的是就構建開放元宇宙所需的互操作性標準進行全行業合作，未來將探討缺乏互操作性阻礙元宇宙部署的原因，以及如何協調和加速標準開發組織 (SDO) 定義並推動元宇宙標準制定相關的工作。聯盟的參與者涵蓋了全球最大的互聯網企業、晶片製造商以及遊戲公司，還包括萬維網聯盟 (W3C) 等成熟的標準制定機構。 而元宇宙產業所涉及範圍之廣，而其中不論是從早期的區塊鏈、到例如比特幣或是乙太幣等的加密貨幣、一直到NFT的話題，更是從2021年開始延燒，而NFT的發展更是時下年輕人看好的未來發展趨勢，不僅僅是年輕人在跟風潮流，更多的知名藝人、網路紅人及知名IP也都搶搭這波NFT的快速列車，發行屬於自己的NFT。就現在的趨勢來看，「元宇宙」是一個必然會發生，而且將成為下個世代主流網路社群商機的重大趨勢。 伴隨著元宇宙Metaverse的概念興起，推動著時報獎組委會，把數字藝術帶進生活的決心，於是誕生了“DS全球數字藝術獎 ”。該獎項旨在建立WEB 3.0元宇宙產業發展平臺，透過國際賽事，孵化數字藝術，發掘及培養優秀的產業人才。鼓勵有志投入元宇宙發展的人士，實現創作自由，創意自由。與組委會一同打造元宇宙的新未來。 而關於DIGISOUL數字精神，組委會則表示，在人類演化的過程中，每一個時代都有不同形式的藝術浪潮和偉大創作。那股經典的力量就像是藝術的靈魂，像一個巨大的能量，貫穿至每個時代、每位創作者、每個藝術品。WEB 3.0的浪潮裏，在元宇宙理性思惟邏輯架構的演算法之下，原本冰冷的數字環境，什麼是動人的力量？數字藝術的靈魂是什麼？從何傳承？如何創新？DIGI SOUL 數字靈魂，是我們在溝通本次活動的主要精神，在數字藝術創作中，作品是不是有靈魂，這是最珍貴的，你的藝術創作必須是有靈魂、有情感的!我們將透過不同精靈的演示方式，喚醒創作者，找到數字作品動人的力量，我們在尋找數字靈魂夥伴 DIGI SOUL。 【2022DS全球數位藝術獎】由中華民國全國工業總會指導，旺旺中時媒體集團主辦，中華文創發展協會、技嘉科技、VEVEVERSE、easyNFTwallet協辦，金犢獎組委會、金手指獎組委會承辦，徵件期限自即日起至10月20日止，總獎金高達70萬元，所有參賽作品均可角逐最大獎15萬元，參賽主題分為兩大主題，主題一為未來設計師的宇宙重啟計畫，主題二為看見東方美原創NFT圖像，作品形式更是涵括了繪畫、插畫、IP設計、數位雕塑、數位影像以及元宇宙數位資產創作等不同面向進行徵集。此外，組委會還規劃了一系列的相關活動，包括數位創作公益公開課、元宇宙趨勢論壇、入圍者NFT上市工作坊，作品人氣票選、全球巡展等相關活動，皆歡迎有志者共襄盛舉。相關訊息可至https://digisoulmetaverse.com/中進行了解。
SYDNEY, April 10, 2025 /PRNewswire/ -- Manhattan Associates Inc. (NASDAQ: MANH), a global leader in supply chain commerce solutions, announced today that it has been named a Leader in the Gartner Magic Quadrant for Transportation Management Systems for the seventh consecutive year. With the growing complexity of supply chains, it has become critical for enterprises to better orchestrate transportation and distribution processes with a unified supply chain execution solution. Manhattan's cloud-native technology, microservices-based architecture and unified platform provide supply chain and logistics professionals with a distinctive and advanced technology architecture that stands apart from legacy, portfolio offerings in the market. By doing away with silos, it delivers real-time visibility into shipments, offers predictive analytics for better decision-making, delivers the ability to automate manual processes and ultimately eliminates inefficiencies, which is a definite game-changer for companies operating in complex and demanding environments. "We are delighted to be recognised by Gartner as a Leader in TMS," said Bryant Smith, director of Product Management for Manhattan Associates. "This ongoing leadership reflects our commitment to continuous innovation, customer success, and excellence in supply chain execution. We deliver speed and value across various transportation functions and leverage advanced intelligence to solve the largest and most complex transportation challenges." Latest additions to the cloud-native Manhattan Active TM include GenAI capabilities to the platform, and unification of Manhattan Active Yard Management with TMS. It can already be combined with Manhattan Active Warehouse Management, and Labor Management providing companies with a complete, simplified, and unified supply chain execution system that continuously adapts and scales to business needs, and provides a single, comprehensive view of the distribution network, unlocking optimisation opportunities that are impossible with traditional siloed offerings. To download a complimentary copy of the Gartner Magic Quadrant for TMS report, please click HERE. Receive up-to-date product, customer and partner news directly from Manhattan on LinkedIn. Gartner Disclaimer: Gartner, Magic Quadrant for Transportation Management Systems, Brock Johns, Oscar Sanchez Duran, Carly West, Manav Jain, 24 March 2025. Gartner is a registered trademark and service mark and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organisation and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Manhattan Associates: Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers. Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.
Revenue increased by 90.8% YoY to RMB 4,052 million Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentage points increase compared to that of 2023 The total global customer base expanded to 499, adding 154 new customers in 2024 The total number of iCMC projects reached 194, adding 53 new iCMC projects to the portfolio The total backlog grew to US$991 million, representing a 71.3% YoY growth Launched a new production line, BCM2 Line 2, at the Wuxi site, further increased manufacturing capacities The construction of Singapore commercial site is progressing smoothly and well on track for operation commencement by the end of 2025 Winner of the "Best CDMO" Award consecutively in 2023 and 2024 Continue to invest in frontier technology, solidifying the Group's competitiveness and leadership position SHANGHAI, March 24, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its annual results for 2024 (the "Reporting Period"). Dr. Jimmy Li, CEO of WuXi XDC, stated, "The year 2024 has been another year of exceptional growth and remarkable achievements for us, even as we navigated a dynamic macro environment. Our strong performances reflect the relentless dedication of our entire organization, as well as the trust and support from our customers, investors, and stakeholders. We have made significant strides in expanding our global presence, enhancing our in-house technology capabilities, and solidifying our position as a leading CRDMO in the ADC and bioconjugate market. Our focus on customer needs and innovative trends has driven our success, enabling us to deliver high-quality services and solutions. The Singapore commercial site is on track and to be operational by the end of 2025, underscoring our unwavering commitment to a robust global presence by delivering top-tier commercial manufacturing capabilities. Looking ahead, we are excited by the vast market opportunities in the bioconjugate space. We believe that with our strong expertise and integrated capabilities, we will continue to win customers, and increase our market share going forward." Financial Highlights Revenue The Group's revenue increased by 90.8% YoY to RMB4,052.3 million for the year ended December 31, 2024. This increase was primarily attributable to (i) the growth in the number of customers and projects, driven by continued active development of the global ADC and broader bioconjugates market, (ii) our increasing market share through the Group's established position as a leading bioconjugate CRDMO service provider, and (iii) the advancement of the Group's projects into later stages. Gross Profit and Its Margin The Group's gross profit increased by 121.6% YoY to RMB 1,239.8 million, with a gross profit margin of 30.6% and a 4.3 percent points increased compared to 2023. This improvement is driven by (i) further improving utilization rate of our manufacturing facilities including the swift ramp-up of new production line (BCM2 L1), (ii) the enhanced overall operation and manufacturing efficiency, (iii) the continuous efforts in cost control, and (iv) the continuous efforts in procurement strategy optimization. Adjusted Net Profit Before Interest Income and Expense and Its Margin The Group's adjusted net profit before interest income and expense increased by 171.3% YoY to RMB 992.0 million. The margin of adjusted net profit before interest income and expense improved to 24.5% in 2024, a 7.3 percent points increase compared to that of 2023. Adjusted Net Profit and Its Margin The Group's adjusted net profit increased by 184.8% YoY to RMB 1174.0 million. The margin of adjusted net profit improved to 29.0% in 2024, a 9.6 percent points increase compared to that of 2023. Net Profit and Its Margin The Group's net profit increased by 277.2% YoY to RMB 1,069.6 million. The net profit grew faster than revenue and business growth, mainly attributed to the increase in gross profit margin, improvement in operation efficiency, continuous stringent cost control measures, and increased interest income. The net profit margin of the Group improved to 26.4% in 2024, a 13.0 percentage points increase compared to that of 2023. Customers and Projects Highlights We have continuously expanded our customer base, reaching a cumulative total of 499, through strong customer-enabling empowerment. Notably, 13 out of top 20 global pharmaceutical companies (*ranked by 2023 revenue) have partnered with us in various stages of projects. In 2024, 60% of the large-scale China-to-global out-licensing deals involving ADC (total deal value exceeding US$1 billion) were our customers, which is a strong testament to our leading position in the bioconjugate industry. As of the reporting date, all customers' out-license assets empowered by WuXi XDC are in active development. The "Enable, Follow, and Win the Molecule" strategy continued to drive sustained and rapid project growth. The total number of integrated projects ("iCMC projects") is 194, with 53 newly signed integrated projects. The Group has secured 8 PPQ projects and one commercial stage project. Additionally, our platform has achieved the highest number of IND approvals globally in 2024. The Group has a diversified project base covering both innovative ADC and broader bioconjugate ("XDC") projects. The total number of integrated ADC projects reached to 177, and the number of integrated XDC projects increased to 17. The Group is committed to pioneering the development of the bioconjugate industry and meeting various development requirements from our customers. In 2024, the Group explored over 4,200 molecules of various modalities, including bispecific ADC, dual-payload ADC, DAC, AOC, APC, ACC etc. Fully Integrated R&D Technology Platform The Group strives to empower customers with cutting-edge conjugation and payload-linker technologies, along with extensive expertise of bioconjugate development capabilities to fulfill diverse R&D requirements. Conjugation Technology—The proprietary WuXiDARx™ technology aims to meet customers' demands for highly homogeneous ADCs with a range of distinct DAR values. As of the reporting date, 45 pre-clinical candidates and 7 clinical projects were successfully developed by using our WuXiDARx™ technology. Linker-payload technology—The newly launched proprietary X-LinC technology can significantly improve the plasma stability by replacing the maleimide connector, hence potentially improving ADC stability and therapeutic window. The Group is also developing its proprietary hydrophilic linker, an innovative linker designed to improve hydrophilicity and stability. Meanwhile, Proprietary CPT payload as well as other novel payloads are also being developed. By leveraging a diverse suite of in-house technology, extensive expertise and collaborations with third parties, the Group enables customers to optimize ADC and XDC design in early stage while ensuring scalability and quality for clinical and commercial production and manufacturing. Capacity Expansion and Business Operation Updates The Group has adopted a centralized quality assurance system across its "All-in-One" manufacturing facilities in the Wuxi site to safeguard product quality. During the reporting period, the Group maintained a high execution standard and delivered a 100% success rate to global customers. All of the Group's manufacturing operations are conducted in accordance with the GMP regulations set by FDA, EMA and NMPA. The Group has completed more than 137 GMP audits from global customers, including 16 audits by EU Qualified Persons. The construction of Singapore site is ongoing and the new facility is targeted to be operational by the end of 2025. With the launch of BCM2 L2, the Wuxi site has further increased its mAb and DS manufacturing capacities. In response to the fast-growing demands, the Group has announced the plan of adding two DP lines at the Wuxi site. Specifically, the DP3 facility ("DP3") is expected to be operational by the first half of 2025, and the DP5 facility ("DP5") is currently under design and scheduled to be launched in 2027. The total number of full-time employees increased by 73.3% YoY to 2,041 in the Group, driven by rapid business growth and the Group's capacity expansion. The Group is committed to strengthen ESG governance and received an 'A' rating in the Wind ESG rankings in 2024, reflecting our exceptional performance in corporate responsibility, risk management, and ethical business conduct. Key Financials （For the Year Ended December 31） Key Financials (RMB Mn) 2024 2023 YoY% Revenue 4,052.3 2,123.8 90.8 % Gross Profit Margin (%) 1,239.8 30.6% 559.6 26.3% 121.6 % Adjusted Net Profit Before Interest Income and Expense Margin (%) 992.0 24.5% 365.6 17.2% 171.3 % Adjusted Net Profit Margin (%) 1,174.0 29.0% 412.3 19.4% 184.8 % Net Profit Margin (%) 1,069.6 26.4% 283.5 13.4% 277.2 % -***- About WuXi XDC WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) is a leading global CRDMO focused on bioconjugate market. It provides end-to-end contract research, development and manufacturing services for ADC and broader bioconjugates. For more information about WuXi XDC, please visit: www.wuxixdc.com Contacts Investor: wuxixdc.ir@wuxibiologics.comMedia: wuxixdc_pr@wuxibiologics.comBD: wuxixdc_info@wuxibiologics.com Forward-Looking Statements This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our customers' intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. Use of Adjusted Financial Measures (Non-IFRS Measures) We have provided adjusted net profit, adjusted net profit margin, adjusted net profit before interest income and expense, margin of adjusted net profit before interest income and expense and adjusted diluted earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses, gains or losses from equity investments and foreign exchange gains or losses, and are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.
NEW YORK, March 24, 2025 /PRNewswire/ -- Spring has officially arrived, and with it comes the need to spruce up and update your skincare routine. COSRX, the viral K-beauty loved for its effective and affordable formulas, is offering an exclusive opportunity to bloom into your best skin yet with the Amazon Big Spring Sale 2025. Running from March 25th to 31st, this sale features up to 66% off on COSRX's fan-favorite products that hydrate, rejuvenate, and reveal your most radiant skin. From TikTok-viral face masks to dermatologist-approved Snail Essence, COSRX has everything you need to glow this spring. COSRX Offers Unmissable Deals in Amazon's Big Spring Sale 2025 Embrace the warm sunshine and conquer dry winds with COSRX's curated selection of best-sellers, now available at unbeatable prices. Among the must-have products featured in this promotion are: Advanced Snail Mucin Glass Glow Hydrogel Mask: Formulated with a high concentration of Snail Secretion Filtrate to deliver powerful all-in-one skincare benefits in a single use. Using innovative hydrogel technology, the mask gradually turns transparent as its active ingredients are absorbed into the skin, offering hydrating, brightening, soothing, and firming effects while improving overall skin texture and radiance. Uniquely, the mask can also be used overnight, making it ideal for overnight care. Advanced Snail 96 Mucin Power Essence: A lightweight, deeply hydrating essence that infuses hydration, improves elasticity and soothes the skin. Its versatility allows it to be used as a primer for a smooth makeup base, mixed with foundation for a dewy glow, or applied to calm sunburned skin and replenish moisture. Advanced Snail 92 All in one Cream 100: A rich moisturizer that strengthens the skin barrier, locks in hydration and soothes the skin for a plump, dewy finish. It can also be used as a primer before makeup, creating a smooth, flawless base. Glass Skin Starter Set: The Set, available exclusively on Amazon, includes two full-sized Advanced Snail 96 Mucin Power Essences and a travel-size The Retinol 0.1 Cream, curated to achieve Mirror Skin – an evolution beyond glass skin. The cult-favorite Snail Essence deeply hydrates and strengthens the skin barrier, while The Retinol 0.1 Cream smooths fine lines and refines texture with minimal irritation. Together, these powerhouse formulas work in synergy to deliver radiance, clarity, and a healthy glow. The 6 Peptide Skin Booster Serum: A powerhouse serum infused with six peptides to support radiant, youthful skin, leaving it visibly firmer and healthier. One reviewer raved that they "looked 15 years younger" after using the serum for a month, adding that their skin "feels tightened and moisturized," plus their "radiance is out of this world." The same person went on to crown the product a "game changer." Ultimate Nourishing Rice Overnight Spa Mask: A deeply hydrating cream that nourishes and brightens the skin. Use a single layer as a daily moisturizer or layer up for an overnight sleeping mask – no rinsing needed. Vitamin E Vitalizing Sunscreen SPF 50+: This SPF offers powerful antioxidant protection with vitamin E, helping defend against free radical damage while replenishing moisture. Additionally, mattifying silica and cotton extract help control excess oil, making it ideal for a balanced finish. Don't miss out on this limited-time opportunity to spring into your best skin yet. Visit the COSRX store on Amazon from March 25th to 31st and stock up on all your skincare essentials before the sale ends! About COSRX: With its powerful yet affordable skincare solutions, COSRX has quickly become one of America's favorite skincare brands. Using a minimal number of highly effective natural extracts in concentrated doses, COSRX products deliver visible results by treating the skin with only the essentials it needs and nothing it doesn't. Find its best-selling skincare solutions at retailers nationwide, including https://www.cosrx.com, Amazon, ULTA, Revolve, Dermstore, Nordstrom and Target. COSRX is also on Instagram + TikTok.
NEW YORK, March 24, 2025 /PRNewswire/ -- COSRX, the TikTok-viral K-Beauty brand celebrated for its effective and affordable skincare solutions, has hit a major milestone as its consumer-first skincare bundles, claim top spots on Amazon US. This achievement highlights COSRX's dedication to addressing real skincare needs by offering curated solutions designed to enhance customer experience and deliver greater value. COSRX Tops Amazon Rankings with Insight-Driven Skincare Bundles That Prioritize Consumer Needs By analyzing consumer insights, COSRX identified a demand for simplified, results driven skincare routines, leading to the creation of bundles that directly align with what today's shoppers want: convenience, efficacy, and affordability. This consumer-centric approach has propelled the Glass Skin Starter Set to the #1 position and the All About Snail Set to #3 in Amazon's Skincare Sets category, proving that COSRX's commitment to solving skincare concerns resonates deeply with its audience. Glass Skin Starter Set: Achieve Mirror Skin with COSRX's Amazon-Exclusive Set The Glass Skin Starter Set, available exclusively on Amazon, is a results driven bundle designed to take your glow one step further to achieve the coveted Mirror Skin look. Created with consumer wants and needs in mind, this set pairs two full sized bottles of the cult favorite Advanced Snail 96 Mucin Power Essence and one travel-size The Retinol 0.1 Cream, delivering a powerful combination of deep hydration and gentle skin renewal. From viral phenomenon to timeless skincare essential, the Advanced Snail 96 Mucin Power Essence has transcended trends to become a global icon. Powered by 96% snail mucin, this renowned essence is celebrated for its ability to fortify the skin barrier while flooding the skin with intense, long-lasting hydration. A cult favorite that consistently sells out, it has solidified its place as a must-have for anyone in pursuit of healthy, plump, and luminous skin. Defying the misconception that retinols are harsh, The Retinol 0.1 Cream offers a balanced blend of efficacy and gentleness. Formulated with 0.1% pure retinol, it softens fine lines, improves skin texture and tone, and promotes a youthful glow - all while minimizing irritation, even for first-time retinol users. Designed for versatile applications, it is gentle enough for the delicate eye area and suitable for use on the neck, chest, and face. All About Snail Set: The Ultimate Snail-Infused Skincare Routine The All About Snail Set is a must-have for those seeking to fully harness the power of snail mucin in their skincare routine. This travel sized collection features COSRX's best selling snail-based products including: Advanced Snail Mucin Gel Cleanser: Gently cleanses without stripping the skin Advanced Snail 96 Mucin Power Essence: Deeply hydrates and plumps the skin Advanced Snail 92 All in One Cream: Strengthens the skin barrier for healthier, more resilient skin Advanced Snail Peptide Eye Cream, Revives and brightens the delicate eye area, reducing puffiness and fine lines. The All About Snail Set offers a complete, easy-to-use skincare routine for radiant, glowing skin wherever you go. Take it on travels or use daily to transform skin with the power of snail mucin. "COSRX has always prioritized the consumer experience, and these rankings prove that our insights into what people truly want have made a significant impact. By creating skincare bundles that address real skincare concerns and offering them in convenient, ready-to-use sets, we've been able to provide real value. The top rankings on Amazon is a direct result of us putting consumers at the center of our strategy and offering simple, effective skincare solutions that truly work" a brand representative of COSRX claims. As demand for COSRX best-sellers rises, customers can now take advantage of an exclusive offer of up to 66% off during the upcoming Amazon Big Spring Sale 2025, starting on March 25th. Don't miss the opportunity to secure the top ranked products during this exciting Big Spring Sale. About COSRX: With its powerful yet affordable skincare solutions, COSRX has quickly become one of America's favorite skincare brands. Using a minimal number of highly effective natural extracts in concentrated doses, COSRX products deliver visible results by treating the skin with only the essentials it needs and nothing it doesn't. Find its best-selling skincare solutions at retailers nationwide, including https://www.cosrx.com, Amazon, ULTA, Revolve, Dermstore, Nordstrom and Target. COSRX is also on Instagram + TikTok.
GCMA號召全民動起來！親子共融 燃燒熱血運動精神 原訂在陽光下展開的跳繩盛宴，卻在3月15日迎來突如其來的大暴雨！即便天公不作美，風雨也未能澆熄民眾對運動的熱愛，由台灣健康促進成長曲線管理協會（GCMA）主辦的「2025 活力滿滿 成長跳躍 世界紀錄跳繩活動」，依然吸引來自各地的參與者前來挑戰，即便天候不佳，仍有眾多家庭和學童堅持跳完，展現無比的運動精神。 此次活動吸引了數千個家庭報名參加，從學齡兒童到長輩，大家共同期盼能在跳動間感受運動的快樂與成長的力量。同時邀請許多貴賓親臨現場支持，台北市體育局副局長 蔡培林先生、台北市國中學生家長會聯合會 沈文生副總會長、台北市國小學生家長會聯合會林睿豪監事長以及陳麗霞秘書長、GCMA協會榮譽理事長 陳夢琦女士，以及國際扶輪 3522 地區總監 侯玳梁先生(DG D.L.)、第五分區助理總監 許富源(PP Kito)、台北市同慶扶輪社前社長 陳麗真 女士 (PP House)，一同見證了真正的「成長跳躍」精神。 （由左至右依序為國際扶輪 3522 地區秘書長 莊政輝先生(DS Robot)、台北市國小學生家長會聯合會陳麗霞秘書長、林睿豪監事長、台北市國中學生家長會聯合會 沈文生副總會長、GCMA協會榮譽理事長 陳夢琦女士、國際扶輪 3522 地區總監 侯玳梁先生(DG D.L.)、第五分區助理總監 許富源先生(PP Kito)、台北市體育局副局長 蔡培林先生以及台北市同慶扶輪社前社長 陳麗真 女士 (PP House)） 「成長跳躍」響應翻倍 共譜健康樂章 迎來第二屆的「2025成長跳躍」跳繩活動，在台北市政府教育局、台北市國中學生家長會聯合會、及台北市國小學生家長會聯合會的鼎力支持下，報名參與人數從去年的5,000人激增至萬人，創下人數和規模的雙重突破。 除了數字上的大躍進，更進一步提升了全民健康意識，GCMA強調：「規律運動、均衡飲食、充足睡眠」是兒童成長的三大黃金要素，而跳繩運動正是強化心肺功能、鍛鍊骨骼密度、提升專注力的最佳選擇，未來十年間，GCMA將持續推動此項計畫，助力學童成長，並積極推動全民健康。 （孩童＆家長共同齊跳）圖/主辦單位 攤商集結 × 趣味活動 多元體驗 顛覆運動樂趣 「2025成長跳躍」不僅聚焦跳繩，還巧妙融入多種互動體驗區，讓親子關係在運動中得到更多的連結與樂趣！為了運動不再單調，近40家攤商全力支持，齊心打造充滿驚喜與挑戰的活動現場。「NERVE JUMPROPE」帶來高階跳繩體驗教學，挑戰心肺耐力與協調性；「KENDAMA101」的劍玉體驗區則讓孩子們感受傳統遊戲的樂趣，提升專注力和手眼協作能力。 此外，「藝騎來跳跳」設置跳跳床，伴隨著歡樂舞曲，大家盡情跳躍，鍛鍊腿部及核心肌群。最令人興奮的，當然是「傑立高Jelly GO」的超可愛吉祥物——高小傑的現身！高小傑舉辦的見面會吸引了無數粉絲，現場湧現一波又一波的合照熱潮，成為活動的一大亮點。除了高小傑，現場還能見到他的朋友們，包括來自四葉乳業的吉祥物Miruru以及奇多豹，他們的登場也為現場增添了豐富的色彩。 現場舞台區則是邀請YoYo家族的「雲朵姐姐」與「羚羊哥哥」帶來活力四射的演出，讓大小朋友沉浸在熱鬧氛圍中。隨著舞台表演和各式活動的展開，孩子們的笑聲與家長們的熱情回饋交織成最美好的畫面，許多家庭紛紛表示，期待未來能有更多這樣促進親子關係與健康生活的活動！ （藝騎來跳跳設置跳跳床，讓大家盡情跳躍，鍛鍊腿部及核心肌群）圖/主辦單位 （傑立高Jelly GO的超可愛吉祥物——高小傑的現身吸引了無數粉絲）圖/主辦單位提供 （YOYO家族的雲朵姐姐與羚羊哥哥帶來活力四射的帶動跳演出）圖/主辦單位 從跳躍到日常 讓運動成為生活的一部分 GCMA呼籲，運動不該僅止於此刻的熱血，更應成為每個人日常生活的一部分。贊助單位東杰生醫則表示：「『成長跳躍』不只是推動健康生活的契機，更是希望通過實踐，讓無論大人小孩，都能在生活中持續感受到運動的正向能量！期待本次活動能夠成為改變大家健康習慣的起點。」 儘管2025年『活力滿滿 成長跳躍』活動圓滿落幕，但GCMA將繼續推動全齡運動理念，成為推動台灣健康未來的核心力量，讓每個人在運動中找到屬於自己的節奏，邁向更健康、更充實的人生！
A12 藝術空間
DS
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
